Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The MHRA has approved these medications for specific indications, and NICE guidelines recommend their use in adults with type 2 diabetes who meet certain criteria (NG28)
High Costs & Systemic Barriers Exacerbate Health Inequities Policy Reforms Are Critical to Address Structural Inequities High Costs and Systemic Barriers Exacerbate Health Inequities: The products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) are priced at roughly $1,000 per month
Most are injectable, though oral semaglutide (Rybelsus) is also available in the UK for type 2 diabetes
Wegovy and Ozempic both reduce appetite
US$ 20.29
US$ 23.36
US$ 24.58
US$ 28.62
